Dietary Supplement Education Alliance is spending "in the five figures" to develop video news release (VNR) promoting supplement ingredients as alternatives to hormone replacement therapy for menopausal symptoms. Slated for release in early to mid August, the VNR will be accessible by every TV station in U.S. for possible inclusion in local news health segments. Two- to three-minute feature will include interviews with two Los Angeles-based doctors. Supplement marketers also are stepping up PR efforts following studies raising concerns about safety of long-term HRT use. GlaxoSmithKline (Remifemin) reps are now calling on family practitioners as well as OB/GYNs. Novogen is alerting independent pharmacists about safety, efficacy of its Promensil supplement, while Rexall (Sundown Menopause Support) is planning additional in-store promotions that may reference articles on HRT studies...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.
